3.28
1.41 (75.40%)
| Previous Close | 1.87 |
| Open | 3.79 |
| Volume | 105,826,173 |
| Avg. Volume (3M) | 4,037,145 |
| Market Cap | 4,900,917 |
| Price / Earnings (TTM) | 0.007 |
| Price / Sales | 54.99 |
| Price / Book | 0.450 |
| 52 Weeks Range |
| Diluted EPS (TTM) | 277.20 |
| Total Debt/Equity (MRQ) | 5.17% |
| Current Ratio (MRQ) | 2.71 |
| Operating Cash Flow (TTM) | -6.70 M |
| Levered Free Cash Flow (TTM) | -4.55 M |
| Return on Assets (TTM) | -80.05% |
| Return on Equity (TTM) | -200.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Bluejay Diagnostics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.83 |
|
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 0.26% |
| % Held by Institutions | 2.48% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Oct 2025 | Announcement | Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules |
| 09 Oct 2025 | Announcement | Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform |
| 07 Aug 2025 | Announcement | Bluejay Diagnostics Provides Second Quarter Business and Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |